Novo Nordisk shares have dropped ~50% since June 2024 due to poor trial results and other negative catalysts. See why I rate ...

The global cardiometabolic drugs market is poised for significant expansion, with market size reaching USD 50 billion in 2021 and expected to surpass USD 70 billion by 2032. The market is projected to ...

The FDA's new rule restricting the sale of compounded semaglutide could make it more difficult for some people to obtain ...

The number of Americans taking cutting-edge weight-loss drugs like Ozempic, Wegovy and Zepbound has skyrocketed in recent ...

Lexicon Pharmaceuticals, headquartered in The Woodlands, announced it will exclusively license its drug LX9851 to the maker ...

Novo Nordisk has experienced a 50% drop due to potential tariffs and recent clinical trial results. Read why I rate NVO stock a strong buy right now.

Novo Nordisk has licensed an oral obesity drug that works via an uncommon mechanism and may help patients maintain their ...

HONG KONG SAR - EQS Newswire - 27 March 2025 - A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited (Uni-Bio Scienc ...

Record-Breaking Revenue of HK$553.0M and Net Profit of HK$82.8M First-ever Dividend was HK$0.277 Cents Per Share ...

Obesity remains a significant public health challenge in the UK, with over 26% of adults classified as obese and an additional 38% considered overweight. This epidemic not only impacts individual ...